Share: Email

PF-00299804 As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

Clinical Trial stock photo

Complete the Trial Form Below:

Check eligibility to participate in the study

  • Enter your zip code

    We'll show you investigators/research sites in this zip.

  • We will contact upto 3 sites within 100 Miles

Qualification Message
‹

Unfortunately, you did not qualify for this study. See details

You may qualify for a future study, please enter your contact information below to get notified.

  • Enter your name

  • Your email helps investigators to follow up with you.

  • Your phone number helps investigators to follow up with you.

  • By clicking this button you agree to our privacy and terms of service policies. Your information is kept completely confidential and shared only with the clinical trial personnel.
Saved Successfully
‹

Your information has been saved successfully. We will notify you incase a matching trial comes up

You might also be interested in other cribriform carcinomas clinical trials in your area







Select Investigators or Research Sites to contact
  • We will contact upto 3 sites within 100 Miles
Send Message to Investigator

  • Enter your name

  • Your email helps investigators to follow up with you.

  • Your phone number helps investigators to follow up with you.

  • Click to see the preview of your message

  • By clicking this button you agree to our privacy and terms of service policies. Your information is kept completely confidential and shared only with the clinical trial personnel.

Study Description

You may be eligible for this study if you meet the following criteria:

  • Conditions: Carcinoma, Non-small Cell
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • +
    Inclusion Criteria:
  • +
    Exclusion Criteria:

Participation Details

This study will explore the safety and efficacy of the oral PanHER inhibitor PF-00299804 in patients with adenocarcinoma of the lung who are either non-smokers (<100 cigarette, cigar or pipe lifetime) or former light smokers ( less than 10 pack-years and stopped at least 15 years) or have known EGFR activating mutation; or patients with HER 2 amplification or mutation.

Additional Information

Source: ClinicalTrials.gov
Clinical Trial Identifier: TX88427

Trial open to limited number of participants
53 users have viewed this page
Need Help?Contact us

Send a Message to TrialX

Your Email:
Your Phone:
Your Message:
   
To Email:
Your Email:
Your Name:
Your Message:

I found a clinical trial, PF-00299804 As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung on the Trialx Patient Navigator Website.

Please click or copy paste the following link:
https://trialx.com/clinicaltrial/88427/carcinoma-non-small-cell-pf-00299804-as-single-ora/

   
Not interested in this trial? Register to get notified for future clinical trials.